Physician profile
Donald Ebersole
NPI 1932179587
$2,376.76
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $272 · 2021: $1,063 · 2022: $757 · 2023: $14.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $445.92 | 2021-2022 | |
| Novo Nordisk INC | $294.35 | 2019-2022 | |
| Pfizer INC. | $279.89 | 2021-2022 | |
| Lilly USA, LLC | $232.87 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $203.82 | 2019-2022 | |
| Amgen INC. | $164.60 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $99.97 | 2019-2022 | |
| Glaxosmithkline, LLC. | $75.38 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $71.19 | 2021-2022 | |
| Abbott Laboratories | $64.61 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.72 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $48.90 | 2020-2022 | |
| Biogen, INC. | $47.89 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.62 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.08 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $31.39 | 2021-2023 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.63 | 2021 | |
| Eisai INC. | $29.70 | 2020 | |
| Dexcom, INC. | $28.54 | 2021 | |
| Ironshore Pharmaceuticals INC. | $23.98 | 2019 | |
| Acadia Pharmaceuticals INC | $17.89 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.49 | 2021 | |
| Ibsa Pharma INC. | $15.31 | 2022 | |
| Si-Bone, INC. | $15.11 | 2022 | |
| Allergan, INC. | $14.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Ebersole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.